Literature DB >> 12009013

Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: the OFELY prospective study.

Patrick Garnero1, Paul Cloos, E Sornay-Rendu, Per Qvist, Pierre D Delmas.   

Abstract

The Asp1211 residue of the 1209AHDGGR1214 sequence of the C-terminal cross-linking telopeptide of type I collagen (CTX) can undergo spontaneous post-translational modifications, namely, racemization and isomerization, which result in the formation of four isomers: the native form (alpha-L) and three age-related forms, that is, an isomerized form (beta-L), a racemized form (alpha-D), and an isomerized/racemized (beta-D) form. Previous studies have suggested that changes in the pattern of type I collagen racemization/isomerization, which can be assessed in vivo by measuring the degradation products of the CTX isoforms, may be associated with alterations of bone structure. The aim of this study was to examine prospectively the value of the different urinary CTX isoforms and their related ratio in the prediction of osteoporotic fractures in 408 healthy untreated postmenopausal women aged 50-89 years (mean, 64 years) who were part of the OFELY cohort. During a median 6.8 years follow-up, 16 incident vertebral fractures and 55 peripheral fractures were recorded in 65 women. The baseline levels of the four CTX isoforms in women who subsequently had a fracture were compared with those of the 343 women who did not fracture. At baseline, women with fractures had increased levels of ratios of native alpha-L-CTX to age-related isoforms (beta-L, alpha-D, and beta-D) compared with controls (p < 0.01). In logistic regression analysis after adjustment for age, prevalent fractures, and physical activity, women with levels of alpha-L/beta-L, alpha-L/alpha-D, and alpha-L/beta-D-CTX ratios in the highest quartile had a 1.5- to 2-fold increased risk of fractures compared with women with levels in the three lowest quartiles with relative risk (RR) and 95% CI of 2.0 (1.2-3.5), 1.8 (1.02-2.7), and 1.5 (0.9-2.7), respectively. Adjustment of alpha-L/beta-L and alpha-L/alpha-D-CTX ratios by the level of bone turnover assessed by serum bone alkaline phosphatase (ALP)- or femoral neck bone mineral density (BMD) decreased slightly the RR, which remained significant for the alpha-L/beta-L-CTX ratio (RR [95%] CI, 1.8 [1.1-3.2] after adjustment for bone ALP, 1.8 [1.03-3.1] after adjustment for BMD, and 1.7 [0.95-2.9] after adjustment for both bone ALP and BMD). Women with both high alpha-L/beta-L-CTX ratio and high bone ALP had a 50% higher risk of fracture than women with either one of these two risk factors. Similarly, women with both increased CTX ratio and low femoral neck BMD (T score < -2.5) had a higher risk of fracture with an RR (95% CI) of 4.5 (2.0-10.1). In conclusion, increased urinary ratio between native and age-related forms of CTX, reflecting decreased degree of type I collagen racemization/isomerization, is associated with increased fracture risk independently of BMD and partly of bone turnover rate. This suggests that alterations of type I collagen isomerization/racemization that can be detected by changes in urinary CTX ratios may be associated with increased skeletal fragility.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12009013     DOI: 10.1359/jbmr.2002.17.5.826

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  29 in total

Review 1.  Clinical utility of bone markers in the evaluation and follow-up of osteoporotic patients: why are the markers poorly accepted by clinicians?

Authors:  J J Stepan
Journal:  J Endocrinol Invest       Date:  2003-05       Impact factor: 4.256

Review 2.  Bone quality: where do we go from here?

Authors:  Mary L Bouxsein
Journal:  Osteoporos Int       Date:  2003-08-29       Impact factor: 4.507

Review 3.  Bone turnover markers: use in osteoporosis.

Authors:  Kim Naylor; Richard Eastell
Journal:  Nat Rev Rheumatol       Date:  2012-06-05       Impact factor: 20.543

Review 4.  Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease: potential uses and pitfalls.

Authors:  Serge Cremers; Patrick Garnero
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 5.  The role of collagen in bone strength.

Authors:  S Viguet-Carrin; P Garnero; P D Delmas
Journal:  Osteoporos Int       Date:  2005-12-09       Impact factor: 4.507

Review 6.  Bone remodeling markers: assessment of fracture risk and fracture risk reduction.

Authors:  Aubrey Blumsohn
Journal:  Curr Osteoporos Rep       Date:  2003-12       Impact factor: 5.096

7.  Considerations for development of surrogate endpoints for antifracture efficacy of new treatments in osteoporosis: a perspective.

Authors:  Mary L Bouxsein; Pierre D Delmas
Journal:  J Bone Miner Res       Date:  2008-08       Impact factor: 6.741

Review 8.  Is bone quality associated with collagen age?

Authors:  D J Leeming; K Henriksen; I Byrjalsen; P Qvist; S H Madsen; P Garnero; M A Karsdal
Journal:  Osteoporos Int       Date:  2009-03-28       Impact factor: 4.507

Review 9.  Bone markers in osteoporosis.

Authors:  Patrick Garnero
Journal:  Curr Osteoporos Rep       Date:  2009-09       Impact factor: 5.096

Review 10.  The contribution of collagen crosslinks to bone strength.

Authors:  Patrick Garnero
Journal:  Bonekey Rep       Date:  2012-09-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.